Endocrinology
Endocrinology PharmDs Show Value at Nebraska Medicine
Type 2 diabetes management shifting to guideline-directed therapy as Nebraska Medicine pharmacists improve outcomes ...
JUNE 27, 2026
UMass Improved Diabetes Outcomes With Specialty Pharmacy Partnership
UMass Memorial and Shields Health Solutions partner to improve diabetes care with pharmacist-led coaching that ...
MAY 7, 2026
AI Platform Adds GLP-1 Navigator
The artificial intelligence–powered pharmacy navigation platform Scripta Insights has added an expert-driven ...
SEPTEMBER 8, 2025
Pharmacist-Managed Diabetes Program Slashes HbA1c Levels
A pharmacist-managed diabetes care program reduced hemoglobin A1c levels from approximately 9.4% at baseline to ...
AUGUST 17, 2025
‘GLP-1s for Everything!’: Balancing Access With Sustainability
Glucagon-like peptide-1 receptor agonists are moving far beyond their established uses for managing type 2 diabetes ...
AUGUST 16, 2025
GLP-1s Slay Yet Another Condition: Acute Pancreatitis
In a study presented at DDW 2025, GLP-1s appeared to protect patients with chronic pancreatitis from developing ...
AUGUST 15, 2025
GLP-1 Compounding: Expect Inspections
503A compounding pharmacies can expect more inspections from their state boards of pharmacy and audits from PBMs ...
MARCH 14, 2025
GLP-1 ‘Shadow System’ Of Internet Sellers Poses A Major Safety Concern
Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonists are evading FDA scrutiny and patient ...
DECEMBER 16, 2024
‘A War Brewing’ Over GLP-1 Agonist Production
Are glucagon-like peptide-1 agonist drugs such as semaglutide and tirzepatide too complex for 503A and 503B ...
NOVEMBER 21, 2024
Can Machine Learning Predict GLP-1 Responders?
Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond ...
NOVEMBER 20, 2024
FDA and State Boards Eye GLP-1s Amid Larger Compounding Scrutiny
The regulatory environment surrounding pharmacy compounding has rarely been as challenging as it is today, ...
OCTOBER 4, 2024
Report: GLP-1 Adherence Rates Lower Than Expected
Glucagon-like peptide-1 agonists have exploded in use and popularity to treat obesity in nondiabetic patients since ...
JULY 25, 2024
